Evotec AG today announced the completion of the squeeze-out process to acquire all of the remaining shares of DeveloGen AG from its minority shareholders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/squeeze-out-process-for-develogen-completed-5041
Evotec and Harvard University Expand Strategic Alliance into Kidney Disease
Evotec AG today announced a second strategic alliance with Harvard University, this time including Brigham and Women’s Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-expand-strategic-alliance-into-kidney-disease-5039
Evotec Receives 4th Milestone Payment in 2011 as Part of its Discovery Alliance with Boehringer Ingelheim
Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-4th-milestone-payment-in-2011-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5037
Nine months results: Upside materialising
Evotec AG today reported financial results and corporate updates for the first nine months of 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/nine-months-results-upside-materialising-5034
Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi achieved
Evotec AG today announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/two-milestones-in-fragment-based-drug-discovery-alliance-with-shionogi-achieved-5030
Evotec and APEIRON Biologics start next project on the Cbl-b target
Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-biologics-start-next-project-on-the-cbl-b-target-5028
Second multi-target collaboration with UCB announced
Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/second-multi-target-collaboration-with-ucb-announced-5026
Acquisition of remaining 30% of Indian Joint Venture from DIL
Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/acquisition-of-remaining–30-of-indian-joint-venture-from-dil-5024
Ad hoc: Evotec and Roche agree to develop compound that could slow the progression of Alzheimer’s disease
Evotec AG and Roche AG today announced that they have entered into an exclusive world-wide license agreement for the development and commercialisation of Evotec’s MAO-B inhibitor to treat Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-roche-agree-to-develop-compound-that-could-slow-the-progression-of-alzheimers-disease-5597
Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease
Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-roche-agree-to-develop-compound-that-could-slow-the-progression-of-alzheimers-disease-5022